BR0316923A - Mitoneet polypeptide of mitochondrial membranes, their modulators and methods for their use - Google Patents

Mitoneet polypeptide of mitochondrial membranes, their modulators and methods for their use

Info

Publication number
BR0316923A
BR0316923A BR0316923-5A BR0316923A BR0316923A BR 0316923 A BR0316923 A BR 0316923A BR 0316923 A BR0316923 A BR 0316923A BR 0316923 A BR0316923 A BR 0316923A
Authority
BR
Brazil
Prior art keywords
methods
modulators
polypeptide
miponeet
bind
Prior art date
Application number
BR0316923-5A
Other languages
Portuguese (pt)
Inventor
Jerry R Colca
William G Mcdonald
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of BR0316923A publication Critical patent/BR0316923A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants

Abstract

"POLIPEPTìDEO MITONEET DE MEMBRANAS MITOCONDRIAIS, SEUS MODULADORES E MéTODOS PARA UTILIZAçãO DO MESMO". A invenção diz respeito, de um modo geral, a uma família de polipeptídeos de membranas mitocondriais que se ligam a tiazolodinodionas antidiabéticas, sensibilizadores de insulina, e seq³ências de ácidos nucléicos que codificam a família de polipeptídeos. A invenção diz respeito a métodos de identificação de agentes terapêuticos que se ligam aos polipeptídeos da presente invenção. A invenção diz respeito ainda a métodos úteis para o tratamento ou modulação de desordens metabólicas em mamíferos em necessidade desse efeito biológico."MIPONEET MIPONEET MIPONE POLYPEPTIDE, ITS MODULATORS AND METHODS FOR THE SAME USE". The invention relates generally to a family of mitochondrial membrane polypeptides that bind to antidiabetic thiazolodynamines, insulin sensitizers, and nucleic acid sequences encoding the polypeptide family. The invention relates to methods of identifying therapeutic agents that bind to the polypeptides of the present invention. The invention further relates to methods useful for the treatment or modulation of metabolic disorders in mammals in need of such biological effect.

BR0316923-5A 2002-12-06 2003-11-25 Mitoneet polypeptide of mitochondrial membranes, their modulators and methods for their use BR0316923A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43152002P 2002-12-06 2002-12-06
PCT/US2003/037476 WO2004053059A2 (en) 2002-12-06 2003-11-25 Mitoneet polypeptide from mitochondrial membranes, modulators thereof, and methods of using the same

Publications (1)

Publication Number Publication Date
BR0316923A true BR0316923A (en) 2005-10-18

Family

ID=32507744

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0316923-5A BR0316923A (en) 2002-12-06 2003-11-25 Mitoneet polypeptide of mitochondrial membranes, their modulators and methods for their use

Country Status (8)

Country Link
US (1) US20050043361A1 (en)
EP (1) EP1585391A4 (en)
JP (1) JP2006515171A (en)
AU (1) AU2003295843A1 (en)
BR (1) BR0316923A (en)
CA (1) CA2508346A1 (en)
MX (1) MXPA05006035A (en)
WO (1) WO2004053059A2 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2382814T3 (en) 2005-05-17 2012-06-13 Merck Sharp & Dohme Ltd. Cis-4 - [(4-chlorophenyl) sulfonyl] -4- (2,5-difluorophenyl) cyclohexanopropanoic acid for cancer treatment
WO2007087246A2 (en) 2006-01-24 2007-08-02 Merck & Co., Inc. Jak2 tyrosine kinase inhibition
US8691825B2 (en) 2009-04-01 2014-04-08 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
WO2011046771A1 (en) 2009-10-14 2011-04-21 Schering Corporation SUBSTITUTED PIPERIDINES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF
WO2011163330A1 (en) 2010-06-24 2011-12-29 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
US8946216B2 (en) 2010-09-01 2015-02-03 Merck Sharp & Dohme Corp. Indazole derivatives useful as ERK inhibitors
WO2012087772A1 (en) 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
WO2012109495A1 (en) * 2011-02-09 2012-08-16 Metabolic Solutions Development Company, Llc Cellular targets of thiazolidinediones
US9023865B2 (en) 2011-10-27 2015-05-05 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
WO2014052563A2 (en) 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
MX363243B (en) 2012-11-28 2019-03-14 Merck Sharp & Dohme Compositions and methods for treating cancer.
RU2690663C2 (en) 2012-12-20 2019-06-05 Мерк Шарп И Доум Корп. Substituted imidazopyridines as hdm2 inhibitors
US9540377B2 (en) 2013-01-30 2017-01-10 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as HDM2 inhibitors
JOP20190055A1 (en) 2016-09-26 2019-03-24 Merck Sharp & Dohme Anti-cd27 antibodies
AU2018252546A1 (en) 2017-04-13 2019-10-10 Sairopa B.V. Anti-SIRPα antibodies
US10947234B2 (en) 2017-11-08 2021-03-16 Merck Sharp & Dohme Corp. PRMT5 inhibitors
WO2019148412A1 (en) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1/lag3 bispecific antibodies
EP3749292A1 (en) 2018-02-08 2020-12-16 ENYO Pharma Use of modulators of neet proteins for the treatment of infection
WO2020033284A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
EP3833668A4 (en) 2018-08-07 2022-05-11 Merck Sharp & Dohme Corp. Prmt5 inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2311572A1 (en) * 1997-12-17 1999-06-24 Genset S.A. Extended cdnas for secreted proteins
AU2003223520A1 (en) * 2002-04-12 2003-10-27 Mitokor Targets for therapeutic intervention identified in the mitochondrial proteome

Also Published As

Publication number Publication date
WO2004053059A2 (en) 2004-06-24
AU2003295843A8 (en) 2004-06-30
EP1585391A2 (en) 2005-10-19
MXPA05006035A (en) 2005-08-18
EP1585391A4 (en) 2006-03-15
CA2508346A1 (en) 2004-06-24
AU2003295843A1 (en) 2004-06-30
JP2006515171A (en) 2006-05-25
US20050043361A1 (en) 2005-02-24
WO2004053059A3 (en) 2005-05-19

Similar Documents

Publication Publication Date Title
BR0316923A (en) Mitoneet polypeptide of mitochondrial membranes, their modulators and methods for their use
Volles et al. Vesicle permeabilization by protofibrillar α-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism
BRPI0911385B8 (en) isolated polypeptide, fusion polypeptide, multimer and pharmaceutical composition
BRPI0410041A (en) Methods for Sinus Headache Treatment
BR9813968A (en) Nucleic acid molecules that encode proteins having fructosyl transferase activity and processes to produce long chain inulin
BR0213817A (en) Treatment of insulin resistance syndrome and type 2 diabetes with pde9 inhibitors
BRPI0414435A (en) methods and reagents for the treatment of immunoinflammatory disorders
BR9814276A (en) Surface antigens
BR0308537A (en) Compound, composition, and methods for treating type 2 diabetes and hyperuricemia, modulating insulin resistance and alleviating hyperlipidemia in an individual and prodrug agent
BR0317872A (en) Anti-Inflammatory Drugs
AR020048A1 (en) A DEPENDENT POLYPEPTIDE OF VITAMIN K, A PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS IT, THE USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT, ISOLATED NUCLEIC UNCODE THAT CODIFIES SUCH POLYPEPTIDE AND A HOSPED MAMIFEROUS CELL.
BRPI0514395A (en) therapeutic use of rtp801 inhibitors
ECSP088262A (en) ALBUMIN FUSION PROTEINS
BRPI0409924A (en) substituted amino carboxylic acids
BRPI0410348A (en) compounds and uses thereof in amyloid-beta modulation
BR0313792A (en) Use of erythropoietin protein, method for treatment of iron distribution disorders in diabetes and medicine for its treatment
BRPI0417959A (en) antibody or functional fragment thereof, pharmaceutical composition, method for treating or prophylaxis of stroke and other neurological disorders / disorders in a human, use of an anti-goat antibody, and methods for inhibiting neurodegeneration and / or promoting recovery function in a human patient, to promote axonal growth, to produce an antifungal antibody and to produce an intravenously administered pharmaceutical composition
ES2168361T3 (en) DNA SEQUENCES FOR METALOPROTEASES OF THE MATRIX, ITS PREPARATION AND EMPLOYMENT.
BRPI0607084A2 (en) use of an 11-deoxyprostaglandin compound, composition comprising the same, and compound
BRPI0415781A (en) Method for treating diabetes in a patient and pharmaceutical kit
BR9911917A (en) Compositions comprising gaba and caffeine analogs
DE69637391D1 (en) MODIFIED MYELIN PROTEIN MOLECULES
DK1373502T3 (en) Dopaminergic neuronal survival promoting factors and their causes
WO2000020446A3 (en) Bax-mediated apoptosis modulating reagents and methods
PT816504E (en) ACETYL-HYDROLASE FOR THE ACTIVATING FACTOR OF PLATELETS, AND ITS GENE

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2112 DE 28/06/2011.